2.80MMarket Cap-201P/E (TTM)
3.8800High2.8600Low1.08MVolume3.0100Open2.7600Pre Close3.64MTurnover197.74%Turnover RatioLossP/E (Static)860.72KShares18.810052wk High0.74P/B1.78MFloat Cap2.400052wk Low--Dividend TTM547.83KShs Float3118.4994Historical High--Div YieldTTM36.96%Amplitude2.4000Historical Low3.3560Avg Price1Lot Size
Phio Pharmaceuticals Stock Forum
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is presenting data on its INTASYL compound PH-894 at the ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer conference. The presentation focuses on how PH-894 improves the functionality and cytotoxicity of Natural Killer (NK) cells in fighting cancer:
1. PH-894 leads to pote...
No comment yet